MAPT and Alzheimer disease: This pattern of results is consistent with previous findings in the area of AD vs. HC tau pathological differences [4–5, 22], and supports the use of this tracer as a biomarker for in vivo tau pathology and for examining regional differences in tau accumulation between groups of participants.